LQDA · Liquidia Corporation
$86.22
+2.84% last session
End-of-day data · updated 2026-07-28
Market cap
$8B
Enterprise value
$7B
Trailing P/E
496.6
Forward P/E
14.5
Dividend yield
—
Beta
0.55
Avg volume
2M
Employees
0K
2D change
—
5D change
-5.18%
10D change
5.60%
30D change
8.00%
60D change
36.47%
MTD change
6.43%
YTD change
144.77%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LQDA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Signal Summary as of 2026-07-28
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 22.2% above the 50-day MA ($71.04).
- Price vs 200-day MA: Trading 98.7% above the 200-day MA ($43.69).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.32) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($89.03).
LQDA Price Chart
Loading chart for LQDA…
Fundamentals
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.